Ziprasidone mesylate - the first antipsychotic drug to be evaluated

  According to the official website of NMPA, Jiangsu Enhua Pharmaceutical Co., Ltd (hereinafter referred to as “Enhua Pharmaceutical”) obtained the supplemental application approval for ziprasidone mesylate for injection on September 19th.

  Ziprasidone mesylate is a new type of atypical broad-spectrum antipsychotic drug for the treatment of schizophrenia. Ziprasidone is a 5-hydroxytryptamine and dopamine receptor antagonist, especially with strong affinity for 5-HTA2/DA D2 receptor, which was first marketed in Sweden in September 2000, and then entered the Chinese market in 2007, and has been approved for marketing in more than 50 countries around the world.

  Studies have shown that ziprasidone mesylate is effective for both positive and negative symptoms of schizophrenia, with particularly good effects on negative symptoms, and the drug has a high safety profile. Compared with traditional antipsychotics, ziprasidone mesylate improves cognitive function while improving patients‘ positive symptoms in addition to their negative symptoms, and is significantly better tolerated.

  Currently, ziprasidone hydrochloride tablets are mainly used for short-term and long-term treatment, while ziprasidone mesylate injection is used for the treatment of acute schizophrenia and the clinical treatment of patients with schizophrenia agitation who are not convenient for oral medication. Ziprasidone mesylate has better or comparable efficacy on negative symptoms compared to the widely used olanzapine, quetiapine, and risperidone, and has the advantage of not causing weight gain and elevated serum prolactin levels, and has fewer side effects than the existing atypical antipsychotics.